

26 July 2022

Quarterly Activities Report and Appendix 4C Q4 FY22

- Q4 FY22 unaudited Total Revenue of \$4.7m, reflecting a 236% Year-on-Year (YoY) growth compared to Q4 FY21 (\$1.4m)
- Q4 Sample volumes increased 84% YoY to 651k, reflecting a deployed unit utilisation rate of 64% up from 59% in Q4 FY21
- Two units deployed during the Quarter and a third unit successfully deployed in July bringing the Company's deployed unit base to 11
- FY22 unaudited Total Revenue of \$14.2m, represents 216% growth against FY21 (\$4.5m) and a 3.6% increase on the Prospectus forecast of \$13.7m. This comprises Minimum Monthly Assay Payments (MMAP) and Additional Assay Charges (AAC) of \$13.5m in line with Prospectus forecast, and \$0.7m in Other Revenue (Prospectus \$0.2m)
- 38 contracted and deployed units in total, following five new lease agreements signed in Q4; expanding Chrysos' footprint in Ghana and Canada
- New leases grew Total Contract Value (TCV) to \$558.5m, a 430% increase YoY, with a strong sales pipeline advancing into FY23
- \$92m cash in bank as at 30 June 2022, following an Initial Public Offering (IPO) which raised \$65m in new funds for the Company to support its ongoing global growth

Chrysos Corporation Ltd (ASX:C79) ("Chrysos" or the "Company") is pleased to provide its quarterly cash report and summary of its activities for the Quarter ended 30 June 2022 (Q4 FY22).

Chrysos Managing Director and CEO Dirk Treasure commented: "Our first Quarterly Activities Report as a listed company highlights strong Q4 FY22 Total Revenue growth of 236% year-on-year and reflects the accelerating demand for Chrysos PhotonAssay technology. Despite recent challenges across the global macro-environment and some minor delays in our deployment schedule, we further embedded ourselves with customers across Australia, Canada and Africa, and remain well-positioned to meet the strategic, operational and financial objectives outlined in our April 2022 Prospectus."

Summary of Quarterly and Annual Performance Metrics

Table 1: Key Performance Metrics

	Q4 FY22	YoY comparison to Q4 FY21 (%) (Q4 FY21 Result)	QoQ Comparison to Q3 FY22 (%) (Q3 FY22 Result)
Unaudited Total Revenue ¹	\$4.7m	+236% (\$1.4m)	+20% (\$3.9m)
Total Contract Value (TCV)	\$558.5m	+430% (\$105.4m)	+23% (\$453.6m)
Samples Processed	651k	+84% (354k)	+14% (573k)
Minimum Monthly Assay Payments (MMAP)	\$3.4m	+183% (\$1.2m)	+21% (\$2.8m)
Additional Assay Charges (AAC)	\$0.97m	+782% (\$0.11m)	+20% (\$0.81m)


¹ Revenue is unaudited and includes operating lease and other income



June Quarter 2022

Strong and sustained Quarter-on-Quarter growth reflects the ongoing performance of existing deployed units and the deployment of additional units throughout the FY22 year.

Despite global macro-environment and supply chain challenges, Chrysol was able to deploy three PhotonAssay units whilst experiencing only minor delays. As at 30 June two of the three units were in service, taking total number of deployed units to 10. The 11th unit has since been deployed and is now in service and generating revenue.



MMAP revenue continues to increase in line with Chrysol's growing deployed unit base, providing strong reliable cashflows to the Company for deployed units. AAC revenue also continues to rise both in comparison to the previous Quarter and year-on-year.

Other Income is significantly higher than forecast, and is largely the result of the Company's decision to shore up supply of customer sample jars, which are a key, and non-discretionary, consumable for PhotonAssay. Chrysol has now successfully developed a secondary supplier of sample jars based in Western Australia, and the purchase and subsequent sale of these jars to Chrysol's customers accounts for a substantial component of 'Other Income'.


The Company's FY22 unaudited Total Revenue, comprised of MMAP, AAC and Other Income, is \$14.2m, which is a 3.6% increase on the Prospectus forecast of \$13.7m.



Total Contract Value

Total Contract Value (TCV) was \$558.5m^{2,3} at the close of the period. This reflects the addition of contracted revenue from five new lease agreements signed in Q4, netted off against TCV which converted to invoiced unaudited Revenue during the quarter.

Revenue growth was driven by further unit deployments and strong and sustained utilisation of Chrysos PhotonAssay units, as measured by sample volumes processed (Chart 2). More than 651k samples were processed by Chrysos' deployed units during the Quarter, reflecting YoY growth of 84%. The Q4 deployed unit utilisation rate was 64%, in line with Prospectus forecasts, and up from 59% in Q4FY21.



New Lease Agreements & Deployments

During the Quarter, Chrysos signed five new PhotonAssay lease contracts with new and existing customers, bringing the total number of deployed or contractually-committed units to 38.

The new contracts include two five-year leases (with five-year renewal options), with new customer Britannia Life Sciences which will be deployed to its newly-formed North American subsidiary, Britannia Mining Solutions. The relationship with Britannia Life Sciences enables scope for further unit lease agreements. Two other new lease contracts were signed by Chrysos' existing customer, Intertek, an international testing, inspection and certification Company. Chrysos has also brought on a new customer, Alfred H Knight (AHK). AHK's commitment to quality analysis and its status as an often-used umpire laboratory in the industry aligns well with Chrysos' focus on delivering faster, safer, more accurate and environmentally-friendly analysis.

The 38 committed or deployed units includes 21 units contracted to existing customer MSALABS. It is important to note that this relationship forms part of the Company's long term deployment schedule, which extends out to the end of 2024. Chrysos is conscious of the potential for concentration risk and confirms that at no point during the deployment schedule, is MSALABS expected to account for more than 45% of Chrysos' deployed units. To date, the Company has deployed three units to MSALABS, including a unit to Barrick Gold's Bulyanhulu Gold Mine in Tanzania, a unit to the Morila Gold Mine in Mali (Firefinch) and one to Val d'Or in Quebec, Canada.

ENDS

² TCV is calculated using foreign exchange rates of AUD:USD 0.73, AUD:CAD 0.94 and AUD:GBP 0.56. The USD and CAD rates are based on the average of the 3-month forward curve from Bloomberg in March 2022, per the Chrysos prospectus and GBP rates are based on the average of the 3-month forward curve from Bloomberg in May 2022.

³ TCV represents the future minimum contracted revenue on PhotonAssay leases (both deployed and committed) that are yet to be invoiced at a point in time, which are subject to the Company's contractual performance obligations and where the Directors consider reasonable certainty exists, may include values associated with exercise of option periods.



Investor Webcast

Dirk Treasure, Managing Director and CEO of Chrysos Corporation and CFO, Brett Coventry will host a webcast and conference call facility for analysts and investors at 10.30am AEST today.

The links for pre-registration are available below:

Conference call: <https://s1.c-conf.com/diamondpass/10023093-byd2l12.html>

Webcast: <https://webcast.openbriefing.com/8863/>

About Chrysos Corporation

Headquartered in Adelaide, with operations spanning Australia, Canada and Africa, Chrysos Corporation combines science and software to create technology solutions for the global mining industry. The Company's flagship product PhotonAssay delivers faster, safer, more accurate and environmentally-friendly analysis of gold, silver, copper and other elements. For more information about Chrysos or its PhotonAssay technology, visit www.chrysos.com.au.

For enquiries, please contact:

Catherine Strong	Citadel-MAGNUS	+61 406 759 268	cstrong@citadelmagnus.com
Maddie Seacombe	Citadel-MAGNUS	+61 402 999 291	mseacombe@citadelmagnus.com
Chrysos Investor Relations		+61 8 7078 4571	investors@chrysos.com.au

This announcement was authorised for release by the Board of Chrysos Corporation Limited.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Chrysos Corporation Limited

ABN

76 613 131 141

Quarter ended ("current quarter")

June 2022

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (12 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	3,769	11,349
1.2 Payments for		
(a) research and development	(27)	(109)
(b) product manufacturing and operating costs	(1,329)	(2,042)
(c) advertising and marketing	(191)	(301)
(d) leased assets	(71)	(228)
(e) staff costs	(1,797)	(5,499)
(f) administration and corporate costs	(1,160)	(2,624)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	37	96
1.5 Interest and other costs of finance paid	(168)	(374)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	957
1.8 Other (provide details if material)	-	-
1.9 Net cash from / (used in) operating activities	(938)	1,223
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	(9,170)	(25,471)
(d) investments	-	-
(e) intellectual property	(420)	(1,558)
(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities		-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(9,590)	(27,029)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	65,000	115,000
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(3,320)	(6,908)
3.5	Proceeds from borrowings	-	4,900
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material) (Repayment of Customer Debt)	-	(1,293)
3.10	Net cash from / (used in) financing activities	61,680	111,698

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	40,482	5,768
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(938)	1,223
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(9,590)	(27,029)

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	61,680	111,698
4.5	Effect of movement in exchange rates on cash held	416	390
4.6	Cash and cash equivalents at end of period	92,051	92,051

5. Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts		Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	49,488	22,188
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (term deposits)	42,563	18,300
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	92,051	40,482

6. Payments to related parties of the entity and their associates		Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	96
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<p><i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i></p> <p>Includes directors fees and rent paid to CSIRO for the quarter.</p>		

Quarterly cash flow report for entities subject to Listing Rule 4.7B


7. Financing facilities	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
<i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>		
7.1 Loan facilities	7,500	4,900
7.2 Credit standby arrangements	-	-
7.3 Other (please specify)	-	-
7.4 Total financing facilities	7,500	4,900
7.5 Unused financing facilities available at quarter end		2,600
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
Loan facilities are with the Commonwealth Bank, covenants are to be reported quarterly and is secured by a general security interest over the assets of the Company.		

8. Estimated cash available for future operating activities	\$A'000
8.1 Net cash from / (used in) operating activities (item 1.9)	(938)
8.2 Cash and cash equivalents at quarter end (item 4.6)	92,051
8.3 Unused finance facilities available at quarter end (item 7.5)	2,600
8.4 Total available funding (item 8.2 + item 8.3)	94,650
8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)	101
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Answer:	
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
Answer:	
8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
Answer:	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date:



Authorised by: Chief Financial Officer & Company Secretary
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.